Table 2.
Cox regression analysis for prediction of mortality using single variable.
| β (95% CI) | P value | |
|---|---|---|
| Log Gal-3 | 7.484 (0.873, 64.156) | 0.066 |
| Log PINP | 2.473 (0.216, 28.340) | 0.467 |
| Log PIIINP | 15.380 (1.108, 213.582) | 0.042 |
| Log TIMP-1 | 44.530 (4.367, 454.056) | 0.003 |
| Log MMP-2 | 554.336 (16.800, 17637.141) | <0.001 |
| Log MMP-9 | 0.212 (0.039, 1.159) | 0.073 |
| Log BNP | 28.273 (1.282; 623.754) | 0.034 |
| Age | 1.075 (1.034, 1.117) | <0.001 |
| Sex, male | 0.973 (0.317, 2.986) | 0.973 |
| Creatinine, mg/dl | 1.173 (0.906, 1.520) | 0.226 |
| NYHA Fc | 6.301 (2.483, 15.986) | <0.001 |
| LVEF | 0.996 (0.954, 1.039) | 0.848 |
| Usage of ACEI/ARB | 1.110 (0.410, 3.002) | 0.837 |
| Usage ofβ-blocker | 0.702 (0.271, 1.821) | 0.467 |
| Usage of spironolactone | 0.825 (0.291, 2.344) | 0.719 |
| Usage of digoxin | 0.980 (0.378, 2.541) | 0.967 |
| Ischemic origin of HF | 1.459 (0.563, 3.783) | 0.437 |
| Hypertension | 0.826 (0.315, 2.171) | 0.699 |
| Diabetes mellitus | 2.381 (0.918, 6.172) | 0.074 |
Abbreviations: ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BNP= brain natriuretic peptide; Gal-3= Galectin-3; HF=heart failure; LVEF= left ventricular ejection fraction; MMP = matrix metalloproteinase; NYHA Fc= New York Heart Association functional classification; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase.